ACADIA Pharmaceuticals (ACAD)

ACADIA Pharmaceuticals (ACAD) Stock Price & Analysis


ACAD Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$14.45 - $33.99
Previous Close$22.29
Average Volume (3M)1.58M
Market Cap
Enterprise Value$3.43B
Total Cash (Recent Filing)$366.69M
Total Debt (Recent Filing)$48.10M
Price to Earnings (P/E)-24.4
Feb 26, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding164,180,377
10 Day Avg. Volume1,021,946
30 Day Avg. Volume1,583,117
Standard Deviation0.14
Financial Highlights & Ratios
Price to Book (P/B)12.70
Price to Sales (P/S)26.81
Price to Cash Flow (P/CF)-15.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.43
Enterprise Value/Gross Profit6.77
Enterprise Value/Ebitda-24.75
Price Target Upside56.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12




What was ACADIA Pharmaceuticals’s price range in the past 12 months?
ACADIA Pharmaceuticals lowest stock price was $14.45 and its highest was $33.99 in the past 12 months.
    What is ACADIA Pharmaceuticals’s market cap?
    Currently, no data Available
    When is ACADIA Pharmaceuticals’s upcoming earnings report date?
    ACADIA Pharmaceuticals’s upcoming earnings report date is Feb 26, 2024 which is in 82 days.
      How were ACADIA Pharmaceuticals’s earnings last quarter?
      ACADIA Pharmaceuticals released its earnings results on Nov 02, 2023. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.448 by $0.048.
        Is ACADIA Pharmaceuticals overvalued?
        According to Wall Street analysts ACADIA Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does ACADIA Pharmaceuticals pay dividends?
          ACADIA Pharmaceuticals does not currently pay dividends.
          What is ACADIA Pharmaceuticals’s EPS estimate?
          ACADIA Pharmaceuticals’s EPS estimate is $0.31.
            How many shares outstanding does ACADIA Pharmaceuticals have?
            ACADIA Pharmaceuticals has 164,180,370 shares outstanding.
              What happened to ACADIA Pharmaceuticals’s price movement after its last earnings report?
              ACADIA Pharmaceuticals reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.448. Following the earnings report the stock price went up 4.698%.
                Which hedge fund is a major shareholder of ACADIA Pharmaceuticals?
                Among the largest hedge funds holding ACADIA Pharmaceuticals’s share is Baker Bros Advisors LP. It holds ACADIA Pharmaceuticals’s shares valued at 893M.


                  Company Description

                  ACADIA Pharmaceuticals

                  ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.


                  Top 5 ETFs holding ACAD

                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  Vanguard Health Care ETF
                  Vanguard U.S. Momentum Factor ETF
                  Schwab 1000 Index ETF
                  Vanguard Russell 3000 ETF
                  Up to five ETFs with an Outperform Smart Score that hold ACAD. The ETFs are listed according to market value of ACAD within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  AC Immune SA
                  Aclaris Therapeutics
                  Acorda Therapeutics

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis